Tenaya Therapeutics publica dados do RIDGE-1 sobre a terapia gênica TN-401

17 de maio de 2026

Reportado por IA

A Tenaya Therapeutics, Inc. divulgou um conjunto de slides em 17 de maio de 2026, cobrindo os resultados de seu estudo de Fase Ib/II RIDGE-1 sobre a terapia gênica TN-401. A apresentação foca no tratamento para cardiomiopatia arritmogênica do ventrículo direito associada ao PKP2.

O conjunto de slides foi emitido pela empresa em conexão com a revisão de dados clínicos. Ele fornece detalhes sobre o estudo em andamento do candidato à terapia gênica sob o ticker TNYA na NASDAQ. Nenhum resultado adicional ou número de participantes foi especificado nos materiais divulgados.

Single-dose zilebesiran as add-on therapy lowers systolic blood pressure in KARDIA-2 trial

13 de abril de 2026 Reportado por IA Imagem gerada por IA Verificado

A single, under-the-skin dose of the investigational RNA-interference drug zilebesiran lowered blood pressure when added to standard therapy in adults whose hypertension remained uncontrolled, according to results from the global Phase 2 KARDIA-2 trial of 663 participants published in JAMA.

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

Inovio Pharmaceuticals held its first-quarter 2026 earnings call on May 13 to discuss financial results for the period ended March 31 and provide updates on its DNA medicines platform.

ProQR Therapeutics presents at TIDES USA 2026

15 de maio de 2026 Reportado por IA

ProQR Therapeutics N.V. published its slide deck for a presentation at the TIDES USA 2026 conference. The materials were released on May 15, 2026, in connection with the company's Q1 earnings summary from May 12.

Health

Unapproved gene therapy for longevity set to go on sale

Business

Intellia reports strong phase iii results for hae treatment

Asia

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

A new treatment called Daraxonrasib has shown strong results against advanced pancreatic cancer in a recent clinical trial. The drug targets a genetic mutation long considered impossible to treat effectively.

ARS Pharmaceuticals reports strong start to 2026 in earnings call

15 de maio de 2026 Reportado por IA

ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Enhanced Group begins NYSE trading after SPAC merger

28 de maio de 2026 Reportado por IA

Enhanced Group Inc. started trading on the NYSE in early May following its combination with Paradise Acquisition Corp. The telehealth firm focuses on peptides and performance-enhancing products.

quinta-feira, 18 de junho de 2026, 16:29h

Tenaya Therapeutics publica dados do RIDGE-1 sobre a terapia gênica TN-401

Artigos relacionados

Single-dose zilebesiran as add-on therapy lowers systolic blood pressure in KARDIA-2 trial

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

ProQR Therapeutics presents at TIDES USA 2026

Unapproved gene therapy for longevity set to go on sale

Intellia reports strong phase iii results for hae treatment

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

ARS Pharmaceuticals reports strong start to 2026 in earnings call

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

Enhanced Group begins NYSE trading after SPAC merger

Oncolys president reflects on journey to world-first cancer treatment

Longevity startup doses first patient in vision loss trial

Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

Bioinvent hosts kol event on ovarian cancer therapies

New HIV pill simplifies treatment for complex cases

Rallybio and Avenzo hold merger conference call

Virus injection halts pancreatic tumor growth in trial

Gene-editing drug slashes bad cholesterol 62 percent in trial

Caribou Biosciences presents car-t updates at healthcare conference

Syntara reports positive FDA feedback on amsulostat trial

Este site usa cookies